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1 
2 
3 ABSTRACT 
4 
5 
6 
Uromodulin (Tamm-Horsfall protein) is the most abundant protein excreted in the urine under 
8 
9 physiological conditions. It is exclusively produced in the kidney and secreted into the urine via 
10 
11 proteolytic cleavage. The involvement of UMOD, the gene that encodes uromodulin, in rare 
12 
13 
14 autosomal dominant diseases, and its robust genome-wide association with the risk of chronic 
15 
16 kidney disease suggest that the level of uromodulin in urine could represent a critical biomarker 
17 
18 for kidney function. The structure of uromodulin is complex, with multiple disulfide bonds and 
19 
20 
21 typical domains of extracellular proteins. Thus far, the conditions influencing stability and 
22 
23 measurement of uromodulin in human urine have not been systematically investigated, giving 
24 
25 
inconsistent results. In this study, we used a robust, in-house ELISA to characterize the 
26 
27 
28 conditions of sampling and storage necessary to provide a faithful dosage of uromodulin in the 
29 
30 urine. The levels of uromodulin in human urine were significantly affected by centrifugation and 
31 
32 
vortexing, as well as by the conditions and duration of storage. These results validate a simple, 
34 
35 low-cost ELISA and document the optimal conditions of processing and storage for measuring 
36 
37 uromodulin in human urine. 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
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1 
2 
3 INTRODUCTION 
4 
5 
6 
Urinary biomarkers constitute an essential tool for the diagnosis, classification, and prognosis of 
8 
9 kidney diseases (1). Recent evidence pointed at uromodulin (originally named Tamm-Horsfall 
10 
11 glycoprotein) as a potential urinary biomarker relevant for renal function, chronic kidney disease 
12 
13 
14 (CKD) and hypertension (2,3). Uromodulin is a 105 kD glycoprotein with seven N-glycosylation 
15 
16 sites and a high-mannose chain. The protein contains 616 amino acids including 48 cysteine 
17 
18 residues that are all engaged in the formation of disulfide bonds. Uromodulin contains three 
19 
20 
21 epidermal growth factor (EGF)-like domains and a zona pellucida (ZP) domain, found in many 
22 
23 extracellular proteins, as well as a glycosylphosphatidylinositol (GPI)-anchoring site (3). 
24 
25 
Uromodulin is a kidney-specific protein, that is exclusively synthesized in the epithelial cells 
26 
27 
28 lining the thick ascending limb (TAL) of Henle’s loop (4). After proper trafficking and 
29 
30 maturation in TAL-lining cells, uromodulin reaches the apical plasma membrane, to be cleaved 
31 
32 
and assembled in the urine as polymers forming a gel-like structure (5). 
34 
35 
36 Uromodulin is produced at very high rate in the TAL, and is by far the most abundant 
37 
38 protein in normal urine (excretion: 50-100 mg/day) (6). Functions attributed to uromodulin 
39 
40 
include protection against urinary tract infections; prevention of renal calculi formation by 
42 
43 reducing aggregation of calcium crystals; and influencing transport processes by regulating the 
44 
45 activity of NKCC2 and/or ROMK (7,8). Interest for uromodulin was re-ignited when it was 
46 
47 
48 discovered that mutations in the UMOD gene that codes for uromodulin are responsible for a 
49 
50 series of monogenic disorders (familial juvenile hyperurecemia nephropathy, medullary cystic 
51 
52 kidney disease type 2 or glomerulocystic kidney disease) all known as uromodulin-associated 
53 
54 
55 kidney disease (UAKD) (3). These disorders are characterized by severe tubulointerstitial 
56 
57 damage, defective urinary concentration, hyperuricemia and gout, and progressive renal failure 
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1 
2 
3 (9). The mutations often affect cysteine residues, resulting in conformational changes and 
4 
5 
6 intracellular aggregates of uromodulin. In turn, there is a strong decrease in the secretion of the 
7 
8 protein by the TAL cells and a strong decrease in the urinary excretion of uromodulin (10-12). 
9 
10 Lately, a number of genome wide association studies (GWAS) revealed that variants in the 
11 
12 
13 UMOD gene were strongly associated with markers of renal function and risk of developing 
14 
15 hypertension and CKD in the general population (13-15). The association of uromodulin with 
16 
17 
both monogenic diseases and complex disorders such as CKD and hypertension provides a strong 
 
19 
20 rationale for evaluating its urinary concentration as biomarker for renal function and CKD. 
21 
22 
23 The determination of uromodulin in the urine is hampered primarily by its capacity to 
24 
25 
aggregate and the potential instability of such a complex protein. Documentation of sampling, 
26 
27 
28 processing and storage conditions is thus crucial for accurate uromodulin quantification. Despite 
29 
30 the early characterization of antibodies specific for human uromodulin (16), the few reports on 
31 
32 
uromodulin dosage yielded conflicting results in terms of stability, storage conditions and 
34 
35 processing of human urine (17-20). Important points such as the potential influence of urine 
36 
37 centrifugation or vortexing, acidification or alkalinization, treatment with protease inhibitors, or 
38 
39 
40 normalization for urinary creatinine remain unsolved. Furthermore, earlier immunoassays were 
41 
42 often based on poorly documented anti-uromodulin antibodies. Considering the increasing 
43 
44 interest for a robust determination of uromodulin in the urine, the need for a high-throughput 
45 
46 
47 assay, and the limited and contradictory information available, we developed and characterized a 
48 
49 robust ELISA for uromodulin and used this assay to investigate the stability of uromodulin under 
50 
51 
different treatment and storage conditions of human urine. 
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1 
2 
3 MATERIAL  AND METHODS 
4 
5 
6 
Urine sample collection, storage and handling 
8 
9 
10 Analyses were performed on second morning urine samples collected (mid-stream) in a sterile 
11 
12 container from healthy volunteers aged 18-50 years, and processed within 2 h. This protocol was 
13 
14 
approved by the Ethical Committee of the Université catholique de Louvain. 
 
16 
17 
18 The influence of human urine sample processing on the determination of uromodulin (Fig. 1) was 
19 
20 tested after vortexing the sample for 10 sec (Vortex-Genie 2, FAUST, Schaffhausen, 
21 
22 
Switzerland); centrifugation for 10 min at 3,600 rpm (Eppendorf Centrifuge 5430, Hamburg, 
23 
24 
25 Germany) at room temperature (i.e. standard protocol for urine processing and removing cells 
26 
27 and debris; ref. 21); treatment with protease inhibitors (Leupeptin 1µmol/L; Sigma-Aldrich, St. 
28 
29 
Gallen, Switzerland; sodium azide 10 mmol/L); pH adjustment performed by drop titration with 
31 
32 1N HCl (to pH 2.0) or with 1N NaOH (to pH 8.0) using a Hanna HI 2211 pH meter; dilution 
33 
34 using ultrapure deionized water (Destamat Bi 18E, QCS, Maintal, Germany) vs. TEA buffer 
35 
36 
37 (0.5% Triton X-100, 20 mM EDTA, pH 7.5). The effect of storage conditions was tested by 
38 
39 comparing baseline levels with 1-week and 5-month storage at room temperature, +4°C and - 
40 
41 20°C; 4-month and 8-month storage at -80 ˚C; five cycles of freezing-thawing (sample kept at - 
42 
43 
44 80 ˚C for 48 h followed by thawing on ice). Different sample sets were used to evaluate the 
45 
46 influence of the various processing conditions as described. 
47 
48 
49 
50 
51 
52 
Uromodulin ELISA 
54 
55 
56 The in-house ELISA for uromodulin is a colorimetric based sandwich immunoassay using a 
57 
58 sheep anti-human uromodulin antibody (Meridian Life Science, Memphis, USA; K90071C) as 
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1 
2 
3 the capture antibody. This antibody gives a single arc when tested by immuno-eletrophoresis 
4 
5 
6 against fresh urine. The primary antibody was a monoclonal anti-human uromodulin antibody 
7 
8 (Cedarlane Laboratories, Burlington, USA; CL 1032A) raised in mouse and validated in solid 
9 
10 phase radioimmunoassay. The secondary antibody was a goat anti-mouse IgG (H+L) horseradish 
11 
12 
13 peroxidase conjugated (Bio-Rad, Cressier, Switzerland; 172.1011). The substrate was O- 
14 
15 Phenylenediamine dihydrochloride (OPD) (10mg/tablet) (Sigma-Aldrich). The OPD substrate 
16 
17 
solution was freshly prepared by dissolving a tablet in 25 mL of phosphate-citrate buffer [0.1 M 
 
19 
20 citric acid monohydrate, 0.2 M Na2HPO4], pH 5.5. A volume of 5µL 30% H2O2 was added to 25 
21 
22 mL of substrate solution. Human uromodulin (Millipore, Billerica, USA) was used to establish 
23 
24 
the standard curve, with freshly prepared serial dilutions from the standard stock solution (100 
26 
27 µg/mL). Both the standard curve and a standard sample (uromodulin concentration 25 µg/mL) 
28 
29 were systematically used for quality control (QC). 
30 
31 
32 
The determination of urinary uromodulin by ELISA was carried out as follows: a 96-well 
34 
35 microtiter plate (NUNC MaxiSorp™, eBioscience, Vienna, Austria) was coated with 100 µL of 5 
36 
37 µg/mL capture antibody in coating buffer [500 mM H3BO3, 500 mM KCl, 345 mM NaOH, pH 
38 
39 
40 9.0]. The plate covered with adhesive seal was incubated at 4°C overnight then washed three 
41 
42 times with freshly prepared washing buffer (0.1 % Tween 20 in 10 mM phosphate buffer saline 
43 
44 (PBS) pH 7.2 (PBS-Tween 0.1%)) using ImmunoWash 1575 Microplate Washer (Bio-Rad). 
45 
46 
47 Unoccupied sites on the plate were blocked with 100 µL blocking buffer (0.5 % BSA in 10 mM 
48 
49 PBS, pH 7.2) and incubated at 37°C for 1 h with a slow rotation (100 rpm). The plate was then 
50 
51 
washed three times with washing buffer and placed upside-down on absorbent paper to remove 
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1 
2 
3 testing revealed no significant difference vs. dilution with TEA buffer (data not shown). A 
4 
5 
6 volume of 100 µL per well was distributed into the coated wells after vortexing. Standards and 
7 
8 QC sample were run in duplicate whereas each urine sample was tested in 3 different dilutions. 
9 
10 Deionized water was used as blank. After 1 h incubation at 37°C, the plate was washed three 
11 
12 
13 times and placed on absorbent paper. 100 µL of primary antibody diluted in PBS-Tween 0.1% 
14 
15 (1µg/mL) was dispensed in each well; the plate was incubated at 37°C for 1 h (rotation, 100 rpm) 
16 
17 
18 then washed three times. The secondary antibody diluted 1:2,000 in PBS-Tween 0.1% was added 
19 
20 to the wells for 45 min at 37°C and the plate washed three times. Color was developed by adding 
21 
22 100µL of OPD substrate solution. The plate was incubated at room temperature in the dark for 1 
23 
24 
25 min, and the reaction stopped by adding 50µL of 2M H2SO4 to each well. Optical density 
26 
27 (Infinite M200Pro, Tecan; Grödig, Austria) was read at 492nm and urinary uromodulin 
28 
29 
concentration was determined by referring to the standard curve. Uromodulin levels obtained 
30 
31 
32 using the in-house ELISA were compared to the commercial ELISA from MD Bioproduct (St. 
33 
34 Paul, USA; M036020), following the protocol given by the manufacturer. This test has been used 
35 
36 
in several studies (13,22). Urinary creatinine levels (normalization) were measured using the 
38 
39 Synchron® System Creatinine Assay (Unicell DxC Synchron®, Beckman Coulter, Brea, USA), 
40 
41 following the manufacturer instructions. 
42 
43 
44 
45 
46 
47 
48 Immunoblotting 
49 
50 Kidneys from Umod mice (23) were grounded in liquid nitrogen and homogenized as described 
51 
52 
previously (12). The homogenate was centrifuged at 1000 × g for 15 min at 4°C and the resulting 
 
54 
55 supernatant at 100,000 × g for 120 min at 4°C. The pellet was suspended in homogenization 
56 
57 buffer before determination of protein concentration (Pierce BCA protein assay kit; Thermo 
58 
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1 
2 
3 Fischer Scientific; Rockford, USA). SDS-PAGE for mouse and human samples was performed 
4 
5 
6 under reducing conditions. Samples (20 µg of mouse and human kidney extract; 2µL of urine) 
7 
8 were loaded after being mixed with Laemmli sample buffer and heated for 5 min at 95˚C (kidney 
9 
10 samples). Proteins were separated on 10 % SDS gel and transferred to nitrocellulose membrane 
11 
12 
13 for Western blotting. Membranes were blocked with 5 % milk blot for 30 min at room 
14 
15 temperature then incubated overnight at 4˚C with either sheep or mouse anti-uromodulin 
16 
17 
antibodies (1:400 in 0.5% BSA blocking buffer). Secondary antibodies were goat anti-mouse 
 
19 
20 HPR conjugated (1:10,000) or polyclonal rabbit anti-sheep HRP conjugated (1:1,000), for 1 h at 
21 
22 room temperature. Antigen-antibody reaction was detected by using ECL (Immun-Star HRP, Bio- 
23 
24 
Rad) and light-sensitive film (GE Healthcare, Glattbrugg, Switzerland). The molecular weight 
26 
27 was estimated by running the Precision Plus Protein™ All Blue standard (Bio-Rad). 
28 
29 
30 
31 
32 Deglycosylation and desialylation of uromodulin 
33 
34 Deglycosylation of uromodulin from human urine was carried out using PNGase F (PNGase F 
35 
36 
P0704S, New England Biolabs, Ipswich, USA) following the manufacturer’s protocol, whereas 
37 
38 
39 desialylation was performed according the protocol described by Parsons et al. (24). Briefly, 
40 
41 uromodulin was precipitated from pooled human urine (1.5L) following the protocol of Tamm 
42 
43 
and Horsfall (2), dialyzed overnight at 4˚C and then lyophilized (Virtis, Kloten Switzerland). Dry 
45 
46 uromodulin was solubilized in 2.5M acetic acid (10 mg/ml), heated for 3 h at 82 ˚C, then washed 
47 
48 3 times with 15 mL PBS (pH 7.2) on Centricon (MWCO 30000) cartridge (Millipore). 1.5 µL of 
49 
50 
51 deglycosylated urine and 0.1 µL of desialylated uromodulin (vs. 0.5 µL of untreated urine) were 
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1 
2 
3 Colocalization of uromodulin with NKCC2 was carried out in cryosections of human and mouse 
4 
5 
6 kidney samples as previously described (10,12). Briefly, 5 µm-thick cryosections were blocked 
7 
8 with 1% BSA/0.02% sodium azide-PBS for 30 min at room temperature, incubated for 2 h at 
9 
10 room temperature with the sheep (1:400) or mouse (1:200) antibodies against human uromodulin, 
11 
12 
13 followed by washing and incubation with AlexaFluor633-conjugated donkey anti-sheep or goat 
14 
15 anti-mouse (1:200) for 90 min at room temperature. Uromodulin-stained sections were then 
16 
17 
incubated with a polyclonal rabbit anti-NKCC2 antibody (Millipore; AB3562P; 1:100) for 3 h at 
 
19 
20 room temperature, followed by washing and incubation with Alexafluor488-conjugated goat anti- 
21 
22 rabbit antibodies (1:200). Sections were viewed on a Leica SP5 confocal microscope. 
23 
24 
25 
26 
27 Surface plasmon resonance: Biacore 
28 
29 
30 The interaction between uromodulin and the capture antibody was analyzed by surface plasmon 
31 
32 
resonance, using a Biacore T100 system (GE Healthcare, Uppsala, Sweden). Chemicals were 
34 
35 from Sigma unless otherwise noticed. Binding experiments were performed in PBS buffer pH 7.4 
36 
37 containing 0.2% of Tween 20 at a flow rate of 30 µL/min at 25°C. Ultrapure and filtered water 
38 
39 
40 (“MilliQ”, Millipore, Billerica, USA) was used for preparing all solutions. The carboxymethyl 
41 
42 dextran chip (CMD500L, XanTec bioanalytics, Düsseldorf, Germany) surface (1.2 mm
2 
area) 
43 
44 was cleaned before use by injecting 7 times a 50 mM naOH solution containing 1 M NaCl for 30 
45 
46 
47 sec at a flow rate of 5 µL/min. Surface binding is expressed in terms of changes in response units 
48 
49 (RU) with 1 RU being approximately 1 pg/mm
2
. Sheep polyclonal anti-uromodulin antibody (300 
50 
51 
nM) in PBS-Tween was immobilized by amine coupling to the chip surface activated with 
52 
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loaded on 10 % acrylamide gel and analyzed as described above. 
Immunohistochemistry 
8 
 
 
53 
54 aqueous solutions of 0.4 M 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide and 0.1 M N- 
55 
56 hydroxysuccinimide for 300 sec at 5 µL/min flow rate. For determination of kinetic constants, a 
57 
58 
dilution series of four concentrations (19 nM, 39 nM, 78 nM, 156 nM) of uromodulin was 
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1 
2 
3 injected using the T100 in multichannel mode. The reference channel used in parallel did not 
4 
5 
6 contain immobilized antibody, in order to detect background response and unspecific binding of 
7 
8 analyte to the surface. Between two measurements, the surface was regenerated by injecting 
9 
10 twice 10 mM glycine at pH 2 for 30 sec, which completely removed uromodulin from the 
11 
12 
13 antibody. For data evaluation, the measured sensorgrams were referenced twice, first by 
14 
15 subtracting the signal from the reference channel, and second by subtracting the signal obtained 
16 
17 
from injected pure buffer solution. Kinetic curves were evaluated using Biacore T100 Evaluation 
 
19 
20 Software (v. 2.0.2). A global fit was performed using the entire concentration series. Rate 
21 
22 constants for association and dissociation were calculated by taking a 1:1 binding model as a 
23 
24 
25 basis. 
26 
27 
28 
29 
30 Data analysis 
31 
32 
33 Data were analyzed using Statistical Package for Social Sciences (SPSS) version 19 (IBM Corp., 
34 
35 
36 Armonk, USA). The Pearson correlation coefficient was used for correlation analysis, whereas 
37 
38 ANOVA and paired t-test were used for comparisons between the groups. A Bland-Altman plot 
39 
40 
was used to evaluate agreement between uromodulin levels measured with the in-house ELISA 
42 
43 and commercial kit. Level of significance was set to p<0.05. 
44 
45 
46 
47 
48 
49 
50 
51 
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1 
2 
3 RESULTS 
4 
5 
6 
Characterization of the antibodies  against human  uromodulin 
8 
9 
10 The antibodies used for the in-house ELISA were characterized by immunoblotting and 
11 
12 immunostaining (Fig. 2). Immunoblot analysis of human urine and kidney samples in parallel 
13 
14 
with mouse kidney samples using the sheep polyclonal antibodies detected the uromodulin band 
15 
16 
17 at ~100 kD in all samples except the Umod KO kidney sample. The uromodulin band was also 
18 
19 detected in human urine and kidney samples using the mouse monoclonal antibody (Fig. 2A, top 
20 
21 
panel). Both the polyclonal and monoclonal antibodies also appropriately identified the 
23 
24 deglycosylated and desialylated forms of uromodulin (Fig. 2A, lower panels). 
25 
26 
27 Staining of human and mouse kidney tissue samples with the mouse monoclonal or the sheep 
28 
29 
polyclonal antibodies detected uromodulin in the TAL, where it colocalized with NKCC2 at the 
31 
32 apical surface area (Fig. 2B). Surface plasmon resonance (25) was further used to characterize the 
33 
34 uromodulin – antibody interaction (Fig. 2C). As the isoelectric point of uromodulin (pI = 3.2) is 
35 
36 
37 too low for its immobilization to a carboxymethyl dextran surface, the capture sheep anti- 
38 
39 uromodulin antibodies were immobilized at the surface of a sensor chip, and a dilution series of 
40 
41 uromodulin was injected. For the interaction of immobilized sheep anti-uromodulin antibody 
42 
43 
44 with uromodulin, rate constants for association (kon) and dissociation (koff) of 4 x 10
4 
M
-1
sec
-1 
and 
45 
46 4 x 10
-4 
sec
-1
, respectively, were determined, giving a dissociation constant KD (= koff/kon) of 10 
47 
48 
nM. We also measured a strong binding response for the interaction of mouse anti-human 
49 
50 
51 uromodulin antibody to the sheep anti-uromodulin antibody - uromodulin complex. This situation 
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56 
52 
53 is comparable to the conditions in ELISA (see below). Regeneration of the surface with 10 mM 
54 
55 
glycine at pH 2.0 removed both the antibody and uromodulin. 
57 
58 
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decrease in unindexed (6.40 ± 0.63 vs. 13.27 ± 1.18 µg/mL, respectively, p<0.001) and indexed 
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1 
2 
3 
4 
5 
6 
Characteristics of the ELISA for uromodulin 
8 
9 
10 When tested against purified human uromodulin, the in-house ELISA for human uromodulin 
11 
12 showed a sensitivity (minimum amount of analyte which can be accurately detected) of 2.8 
13 
14 
ng/mL and a linearity (correlation between concentration and optical density) of 1.0 (Fig. 3A). 
15 
16 
17 The inter- and intra-assay variabilities were determined at 3.28% and 5.46%, respectively. The 
18 
19 assay had a detection range between 3.9 and 500 ng/mL. When compared with other assays, the 
20 
21 
in-house ELISA showed a wider range of measurement and lower intra- and inter-assay 
23 
24 variability than commercially available routine kits (Table I). There was a robust correlation 
25 
26 (r=0.905, p<0.001) when comparing the in-house ELISA with the MD Bioproduct kit. The 
27 
28 
29 Bland-Altman plot showed that the mean difference between both methods was -1.47 µg/mL 
30 
31 (95% CI, -3.21 to 0.27 µg/mL) (Fig. 3B). 
32 
33 
34 
35 
36 
37 
38 Influence of processing of urine samples 
39 
40 
41 Since uromodulin has a tendency to aggregate, we first investigated the potential influence of 
42 
43 vortexing and centrifugation on the determination of uromodulin levels in human urine (Table II). 
44 
45 
46 Comparison of fresh samples assayed before and after vortexing revealed a more than 50% 
47 
48 increase in uromodulin levels (unindexed uromodulin: 5.02 ± 0.66 vs. 11.03 ± 1.67 µg/mL, 
49 
50 
51 respectively, p=0.001; indexed uromodulin: 10.84 ± 0.54 vs. 15.90 ± 1.45 mg/gr creat, 
Nephrology Dialysis Transplantation 
59 
60 15 
 
 
42 
 
 
1 
2 
3 (9.97 ± 1.43 vs. 15.66 ± 1.34 mg/gr creat, respectively, p<0.001, n=53) uromodulin levels. 
4 
5 
6 Immunoblotting analyses (Fig. 4) revealed that centrifugation was responsible for the 
7 
8 precipitation of uromodulin in the pellet of cell debris. In comparison with the uromodulin band 
9 
10 detected in fresh, non-centrifuged urine samples, the signal was strongly attenuated in the 
11 
12 
13 centrifuged urine sample while becoming apparent in the resulting pellet. 
14 
15 
16 Alkalinization of fresh urine sample to pH 8.0 did not influence the determination of urinary 
17 
18 uromodulin, as compared with untreated (mean pH 5.68 ± 0.19) samples (unindexed uromodulin: 
19 
20 
21 19.25 ± 4.14 vs. 20.60 ± 5.24 µg/mL, respectively, p=0.179; indexed uromodulin: 17.56 ± 2.28 
22 
23 vs. 18.34 ± 2.67 mg/gr creat, respectively, p=0.260, n=14). Likewise, acidification of urine 
24 
25 
26 samples to pH 2.0 did not result in a significant difference between values from untreated (mean 
27 
28 pH 6.15 ± 0.59) samples (unindexed uromodulin: 10.01 ± 2.25 vs. 9.73 ± 2.07 µg/mL, 
29 
30 respectively, p=0.621; indexed uromodulin: 18.86 ± 8.26 vs. 19.10 ± 8.55 mg/gr creat, 
31 
32 
33 respectively, p=0.782, n=8). 
34 
35 
36 
37 
38 Influence of storage conditions 
39 
40 
41 
In order to cast light on the influence of storage conditions on the stability of uromodulin, we 
43 
44 compared values obtained in samples analyzed at baseline and after 1 week or 5 months storage 
45 
46 at room temperature, +4 ˚C and -20 ˚C. As compared to baseline, storage at either room 
47 
48 
49 temperature or 4°C or even -20°C were associated with decreased levels of both unindexed and 
50 
51 indexed uromodulin (Table III). Addition of protease inhibitors at time of collection had some 
52 
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52 
53 
54 
55 
56 
57 
58 
59 
60 
respectively, p=0.001, n=37). Treating the urine samples with an usual centrifugation protocol 
(10 min, 3600 rpm) also showed a strong effect, since centrifugation yielded a significant 
decrease in unindexed (6.40 ± 0.63 vs. 13.27 ± 1.18 µg/mL, respectively, p<0.001) and indexed 
 
12 
 
 
53 effect on the degradation of the samples conserved at -20°C, but not on those kept at +4°C. In any 
54 
55 
56 case, the addition of protease inhibitors was insufficient to prevent a significant decrease in the 
57 
58 uromodulin levels as compared to baseline values. In contrast, 4-month storage at -80°C was not 
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11 
 
 
1 
2 
3 associated with significant changes in uromodulin levels in untreated samples. Further analyses 
4 
5 
6 revealed a slight but significant decrease after 8 months storage at -80°C (baseline uromodulin: 
7 
8 23.73 ± 1.57 µg/mL vs. 8-month: 20.13 ± 1.17 µg/mL, p=0.023, n=142). Freezing-thawing cycles 
9 
10 
(from -80°C to 0°c) showed no significant changes in the levels of urinary uromodulin as 
12 
13 compared to baseline (Table IV). 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
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7 
22 
41 
 
 
1 
2 
3 DISCUSSION 
4 
5 
6 
Increasing evidence suggests that the level of uromodulin in urine could represent a useful 
8 
9 biomarker for kidney function (3,26). In this study, we validated an efficient and cost-effective 
10 
11 immunoassay and characterized the conditions of sampling and storage necessary to provide a 
12 
13 
14 faithful dosage of uromodulin in human urine. The urinary uromodulin levels were significantly 
15 
16 affected by centrifugation and vortexing, as well as by the conditions and duration of storage. 
17 
18 
19 To develop our in-house ELISA we used commercially available anti-uromodulin 
20 
21 
antibodies and validated their specificity in human and mouse kidney and urine samples. Both 
23 
24 antibodies evidenced the ~100 kD band corresponding to uromodulin on Western blot, either in 
25 
26 native or deglycosylated/desialylated state. They also showed the typical distribution along with 
27 
28 
29 NKCC2 in the apical membrane of the TAL. We used plasmon surface resonance to determine 
30 
31 the binding constant for interaction of the immobilized sheep anti-uromodulin antibody to 
32 
33 uromodulin to 10 nM which is in the expected range for an antibody-protein interaction. The 
34 
35 
36 immunoassay standard curve showed linearity over a broad range of values, allowing the 
37 
38 detection of uromodulin with high sensitivity and very low inter- and intra-assay variability. It 
39 
40 
must be noted that, in contrast with previous results based on immunoblotting (20), dilution of the 
42 
43 samples with deionized water yielded similar results than with TEA buffer. All these features, 
44 
45 combined with an excellent correlation with the most used commercial ELISA, substantiate the 
46 
47 
48 interest of our immunoassay with the advantage of low cost, wide range of detection, and low 
49 
50 variability. 
51 
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56 
52 
53 Our analyses revealed a striking effect of vortexing and centrifugation on the 
54 
55 
determination of uromodulin in the urine. These two procedures yielded variations reaching 50% 
57 
58 of the levels obtained on control, unprocessed samples (Table II). These findings are clinically 
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52 
53 
54 
55 
56 
57 
58 
59 
60 
attenuated with protease inhibitors, which show some effect for samples kept at -20°C - but 
insufficient to prevent a significant degradation. Taken together, these data confirm the fact that 
urine samples should be stored at -80°C and analyzed within 3 months to give the most reliable 
16 
 
 
18 
33 
 
 
1 
2 
3 relevant, because low levels of urinary uromodulin have been suggested to be of diagnostic value 
4 
5 
6 in UAKD (3, 9-11). The effect of vortexing confirms the importance of the aggregation of 
7 
8 uromodulin molecules in the normal urine. Uromodulin is also known to cofractionate with 
9 
10 exosomes (27), the recovery of which is increased by vortexing (28). Uto et al. previously 
11 
12 
13 suggested that uromodulin may be trapped in cell debris or aggregated with crystals (18) after 
14 
15 centrifugation protocols that are usual to remove contamination due to lysis or suspended cells 
16 
17 
(29). Our data confirm these findings and show that centrifugation of urine may decrease the 
 
19 
20 level of uromodulin by ~30%. Thawed urine samples should thus be vortexed but not centrifuged 
21 
22 before assaying uromodulin. 
23 
24 
25 
The question of the stability of uromodulin during different storage protocols is critical 
26 
27 
28 for analyzing large, multicentric cohorts. Previous studies based on small sample size yielded 
29 
30 inconsistent conclusions about the influence of storage duration and temperature (17-20). 
31 
32 
Furthermore, these studies did not take into account normalization for urinary creatinine, which is 
34 
35 usual for kidney biomarkers - at least in a stable situation (29,30). Our results, obtained on a large 
36 
37 number of samples, reveal that short (1 week) and longer (5 month) storage at room temperature, 
38 
39 
40 4°C or -20°C causes a significant decrease in indexed urinary uromodulin levels, largely due to 
41 
42 decreased uromodulin. In contrast, a 4-month storage at -80°C is associated with marginal, non- 
43 
44 significant decrease in the unindexed and indexed values. Of note, the decrease in unindexed 
45 
46 
47 uromodulin levels becomes significant after a 8-month storage at -80°C. The fact that storage of 
48 
49 untreated urine samples at room temperature, 4°C or -20°C significantly decrease the level of 
50 
51 
uromodulin substantiates the observations of Kobayashi et al (20). This effect is only partially 
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1 
2 
3 measurements. Of note, up to 5 freezing-thawing cycles on ice did not affect the stability of 
4 
5 
6 uromodulin stored at -80°C. 
7 
8 
9 Previous studies also reported inconsistent results in terms of treatments (detergents or 
10 
11 TEA buffer, alkalinization) supposed to solubilize aggregates of uromodulin in urine (17-20, 31). 
12 
13 
14 Some of these treatments may interfere with the binding of uromodulin to the ELISA capture 
15 
16 antibody (18). We verified here that dilution with deionized water gave similar results than with 
17 
18 TEA, and that urine alkalinization (or acidification) had no effect on the determination of 
19 
20 
21 uromodulin. These data support the conclusion that dilution of the sample with water before the 
22 
23 assay, combined with vortexing, is an efficient way of disaggregation (31). 
24 
25 
26 In summary, these data indicate that reliable uromodulin measurements can be obtained 
27 
28 
29 from untreated urine samples, provided they are immediately stored at -80°C and assayed within 
30 
31 3 months, with vortexing and dilution with water to prevent aggregation. This methodology will 
32 
33 be useful for high-throughput analyses of uromodulin and its validation as a biomarker for renal 
34 
35 
36 function and risk of CKD. 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
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Kit Detection range 
 
(standard curve) 
Inter-assay 
 
Variability 
Intra-assay 
 
Variability 
In-house 3.9 - 500 ng/mL 3.28% 5.46% 
MD Bioproduct 
 
(Cat. M036020) 
 
2.34 - 150 ng/mL 
 
11.63% 
 
8.36% 
BioVendor 
 
(Cat. RD191163200R) 
 
0.5 - 32 ng/mL 
 
6.4% 
 
2% 
USCN Life Science Inc. 
 
(Cat. E96918 Hu) 
 
3.13 - 200 ng/mL 
 
<12% 
 
<10% 
 
 
 
1 
2 
3 Table I. Comparison of the characteristics of the in-house ELISA for uromodulin and the 
4 
5 available commercial ELISA kits. 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
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 Unindexed 
 
Uromodulin 
 
(µg/mL) 
 
 
 
 
 
P 
Indexed 
 
Uromodulin 
 
(mg/gr creat) 
 
 
 
 
 
P 
 
 
 
N 
Vortex 
 
 
 
No vortex 
11.03 ± 1.67 
 
 
 
5.02 ± 0.66 
 
 
0.001 
15.90 ± 1.45 
 
 
 
10.84 ± 0.54 
 
 
0.001 
 
 
37 
Centrifugation 
 
 
 
 
No centrifugation 
6.40 ± 0.63 
 
 
 
 
13.27 ± 1.18 
 
 
 
<0.001 
9.97 ± 1.43 
 
 
 
 
15.66 ± 1.34 
 
 
 
<0.001 
 
 
 
53 
 
 
 
1 
2 
3 Table II. Effect of sample processing (vortex, centrifugation) on the concentration of uromodulin 
4 
5 in the urine. 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
Urine samples were vortexed for 10 sec. Centrifugation was performed for 10 min at 3600 rpm at 
34 
35 room temperature. Two different sets of samples were used to test the influence of vortexing 
36 (N=37) and centrifugation (N=53). 
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F o r 
Pe 
er 
e 
v ew 
  Unindexed 
 
Uromodulin 
 
(µg/mL) 
 
 
 
 
 
P 
Indexed 
 
Uromodulin 
 
(mg/gr creat) 
 
 
 
 
 
P 
 
 
 
N 
 
 
 
1 week 
storage 
Baseline 12.39 ± 2.41 
 
 
 
 
 
 
0.078# 
22.70 ± 3.35 
 
 
 
 
 
 
0.014# 
 
 
 
 
 
 
13 
RT 6.14 ± 1.34* 13.00 ± 2.34* 
+4 ˚C 7.22 ± 1.60* 11.49 ± 1.50* 
-20 ˚C 9.98 ± 1.96* 18.69 ± 3.18* 
4 month 
storage 
Baseline 36.37 ± 2.62 
 
 
0.354 
24.05 ± 1.26 
 
 
0.412 
 
 
61 
-80˚C 35.47 ± 2.32 23.30 ± 1.25 
 
 
 
 
5 month 
storage 
Baseline 28.50 ± 6.76 
 
 
 
 
 
 
0.068# 
 
 
 
 
0.111# 
26.48 ± 3.45 
 
 
 
 
 
 
0.001# 
 
 
 
 
0.003# 
 
 
 
 
 
 
10 
+4°C 
 
-20°C 
 
+4°C & PI 
 
-20°C & PI 
10.17 ± 3.96* 
 
16.52 ± 5.08* 
 
11.04 ± 4.69* 
 
20.23 ± 5.27*£ 
10.27 ± 2.35* 
15.78 ± 2.73* 
10.80 ± 2.32* 
 
18.71 ± 2.69*£ 
 
47 
 
 
1 
2 
3 Table III. Effect of storage conditions (duration, temperature, protease inhibitors) on the 
4 
5 concentration of uromodulin in the urine. 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 PI, treatment with protease inhibitors (Leupeptin and sodium azide). Three different sets of urine 
46 
samples were used to assess influence of storage after 1 week (N=13), 4 months (N=61) and 5 
48 months (N=10) vs. baseline levels. * p <0.05 storage condition vs. baseline, £ p < 0.05 no vs. 
49 protease inhibitors, paired t tests; # ANOVA 
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  Unindexed 
 
Uromodulin 
 
(µg/mL) 
 
 
 
 
 
P 
Indexed 
 
Uromodulin 
 
(mg/gr creat) 
 
 
 
 
 
P 
 
 
 
N 
 
 
 
 
Freezing- 
thawing cycles 
(-80°C to 0°C) 
Baseline 22.96 ± 4.75  
 
 
 
 
 
 
0.616# 
18.14 ± 2.82  
 
 
 
 
 
 
0.351# 
 
 
 
 
 
 
 
8 
1 
 
2 
 
3 
 
4 
 
5 
22.01 ± 3.81 
 
24.74 ± 4.05 
 
16.74 ± 2.68 
 
16.96 ± 3.36 
 
19.42 ± 4.56 
20.19 ± 3.51 
 
23.67 ± 3.07 
 
18.17 ± 2.58 
 
16.20 ± 1.98 
 
15.91 ± 2.42 
 
32 
 
 
1 
2 
3 Table IV. Effect of freezing-thawing cycles on the concentration of uromodulin in the urine. 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
# ANOVA 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
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1 
